Cambridge Enterprise, University of Cambridge
Cambridge Enterprise exists to help University of Cambridge inventors, innovators and entrepreneurs make their ideas and concepts more commercially successful for the benefit of society, the UK economy, the inventors and the University.
|Address:||Hauser Forum, 3 Charles Babbage Road, Cambridge|
|Membership type:||Cambridge University Department|
Cambridge Enterprise Limited is responsible for the commercialisation of University of Cambridge intellectual property and is a wholly owned subsidiary of the University. Activities include management and licensing of intellectual property and patents, proof of concept funding and support for University staff and research groups wishing to provide expert advice or facilities to public and private sector organisations. Cambridge Enterprise provides access to angel and early stage capital through the Cambridge Enterprise Seed Funds and Cambridge Enterprise Venture Partners, and offers business planning, mentoring and other related programmes.
The University leads the world in transformative research and Cambridge Enterprise is well placed to support the academics to find the best commercialisation route for their innovations either through licensing, company creation or consultancy. Income over the past three years exceeded £27 million, of which over £22 million was distributed to University academics and departments, with the remainder reinvested in patent assets, seed fund pools and support for knowledge and technology transfer services to the University.
The website contains information on technologies available for licensing and details of companies formed with technology arising from the University of Cambridge. Cambridge Enterprise is also responsible for the commercial licensing of research reagents owned by the University.
Three University of Cambridge projects have been selected as winners in GSK’s 2014 Discovery Fast Track Challenge, which is designed to accelerate the translation of academic research into novel therapies.
1 December 2014Read in full
The US Food and Drug Administration (FDA) has approved Lemtrada(TM) (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS), Sanofi and its subsidiary Genzyme have announced.
18 November 2014Read in full
The European Medicines Agency (EMA) has recommended granting AstraZeneca marketing authorisation for Lynparza (olaparib), a first-in-class medicine for the treatment of women with a subtype of ovarian cancer for which there are limited approved treatment options.
3 November 2014Read in full
The difficulty in translating university research into the commercial realm is a well-documented problem. The reason is often that industry and academia are driven by different motivations related to their fundamentally distinct core.
31 October 2014Read in full
Cambridge Enterprise, the University’s commercialisation arm, is expanding its reach with the opening of an adjunct office on the first floor of the University’s School of Clinical Medicine, providing a base on the Addenbrooke’s site for the Cambridge Enterprise Life Sciences team.
30 September 2014Read in full
Inivata, a clinical cancer genomics company focused on harnessing the potential of circulating tumour DNA (ctDNA) analysis to improve cancer testing and treatment, today announced it has raised £4m in a funding round led by Imperial Innovations and including Cambridge Innovation Capital and Johnson & Johnson Development Corporation.
23 September 2014Read in full
Breathing Buildings CEO Shaun Fitzgerald has been elected a Fellow of The Royal Academy of Engineering.
18 September 2014Read in full
Scientists have successfully ‘reset’ human pluripotent stem cells to the earliest developmental state – equivalent to cells found in an embryo before it implants in the womb (7-9 days old). These ‘pristine’ stem cells may mark the true starting point for human development, but have until now been impossible to replicate in the lab
12 September 2014Read in full